ERBB2 AMPLIFICATION LEVEL AND PTPN2 GAIN AS POTENTIAL PROGNOSTIC FACTORS IN METASTATIC HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB

被引：0
|
作者：
Ellegard, Sander [1 ]
Veenstra, Cynthia [1 ]
Perez-Tenorio, Giseh [1 ]
Hallbeck, Anna-Lotta [1 ]
Elander, Nils [1 ]
Stal, Olle [1 ]
机构：
[1] Univ Hosp Linkoping, Oncol, Linkoping, Sweden
来源：
BREAST | 2017年 / 36卷
关键词：
D O I：
10.1016/S0960-9776(17)30690-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO71
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [11] Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
    George Fountzilas
    Christos Christodoulou
    Mattheos Bobos
    Vassiliki Kotoula
    Anastasia G Eleftheraki
    Ioannis Xanthakis
    Anna Batistatou
    George Pentheroudakis
    Nikolaos Xiros
    Irene Papaspirou
    Anna Koumarianou
    Pavlos Papakostas
    Dimitrios Bafaloukos
    Dimosthenis V Skarlos
    Konstantine T Kalogeras
    Journal of Translational Medicine, 10
  • [12] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [13] HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab
    Rodrigo Sánchez-Bayona
    Olga Martínez-Sáez
    Denys Romero-Romero
    Elia Seguí
    Esther Carcelero
    Pablo Tolosa
    Jesús Soberino
    Manuel Alva
    Tomás Pascual
    Laura Lema
    Isabel Garcia-Fructuoso
    Maria Angeles Cobos-Fernandez
    Maria Rey
    Luis Manso
    Angela Aguirre
    Ainhoa Madariaga
    Valeria Sirenko
    Cristina González-Deza
    Paula Blasco
    Astrid Mayhua
    Oleguer Castillo
    Patricia Galván
    Esther Sanfeliu
    Guillermo Villacampa
    Wesley Buckingham
    Mercedes Marín-Aguilera
    Laia Paré
    Patricia Villagrasa
    Charles M. Perou
    Julia Maues
    Fara Brasó-Maristany
    Eva Ciruelos
    Aleix Prat
    npj Breast Cancer, 11 (1)
  • [14] Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases
    Mo, Dun-Chang
    Luo, Peng-Hui
    Huang, Jian-Feng
    JAMA ONCOLOGY, 2023, 9 (07) : 1008 - 1009
  • [15] HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
    Prat, Aleix
    Pascual, Tomas
    De Angelis, Carmine
    Gutierrez, Carolina
    Llombart-Cussac, Antonio
    Wang, Tao
    Cortes, Javier
    Rexer, Brent
    Pare, Laia
    Forero, Andres
    Wolff, Antonio C.
    Morales, Serafin
    Adamo, Barbara
    Braso-Maristany, Fara
    Vidal, Maria
    Veeraraghavan, Jamunarani
    Krop, Ian
    Galvan, Patricia
    Pavlick, Anne C.
    Bermejo, Begona
    Izquierdo, Miguel
    Rodrik-Outmezguine, Vanessa
    Reis-Filho, Jorge S.
    Hilsenbeck, Susan G.
    Oliveira, Mafalda
    Vittoria Dieci, Maria
    Griguolo, Gaia
    Fasani, Roberta
    Nuciforo, Paolo
    Parker, Joel S.
    Conte, PierFranco
    Schiff, Rachel
    Guarneri, Valentina
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (01): : 46 - 54
  • [16] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    Current Oncology Reports, 2005, 7 (1) : 9 - 11
  • [17] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [18] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [19] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
    Milani, Andrea
    Montemurro, Filippo
    Gioeni, Luisa
    Aglietta, Massimo
    Valabrega, Giorgio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
  • [20] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
12345